Qiagen reported better-than-expected Q2 results, exceeding the street and management’s expectations. While a COVID-19 testing sales moderation had been expected, sustained momentum for non-COVID-19 offerings was promising and an important read-across for testing firms. Moreover, considering initiatives to expand the scope of offerings, including tapping the recent monkey pox virus-induced opportunities, the firm’s attractiveness remains intact, which could also result in re-emerging M&A interest ....
